News Archive - 2015

News Archive - 2015

Two return-to-research fellows appointed at the Sanger Institute

Two return-to-research fellows appointed at the Sanger Institute

Sanger Institute and Daphne Jackson Trust support career-break fellowships

Two researchers are returning to research at the Wellcome Trust Sanger Institute following a career break. The Sanger Institute Fellowship was launched in June last year to support talented scientists returning to research after a career break of 12 months or more. The Daphne Jackson Trust is the UK's leading organisation dedicated to realising the potential of scientists and engineers returning to research following a career break of two years or more, taken for family, caring or health reasons.

Dr Jeffrey Barrett to lead Centre for Therapeutic Target Validation

Dr Jeffrey Barrett to lead Centre for Therapeutic Target Validation

Sanger Institute, EMBL-EBI, and GSK initiative selects founding Director

Dr Jeffrey Barrett has been appointed as the founding Director of the Centre for Therapeutic Target Validation (CTTV), a public-private partnership between GSK, the European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust Sanger Institute on the Wellcome Genome Campus in the UK.

Leukaemia-associated mutations almost inevitable as we age

Leukaemia-associated mutations almost inevitable as we age

Researchers estimate that 7 in 10 over 90-year-olds harbour cells with early leukaemia mutations

It is almost inevitable that we will develop genetic mutations associated with leukaemia as we age, according to research published today in Cell Reports. Based on a study of 4219 people without any evidence of blood cancer, scientists estimate that up to 20 per cent of people aged 50-60 and more than 70 per cent of people over 90 have blood cells with the same gene changes as found in leukaemia.

CRISPR collaboration aims to speed drug discovery

CRISPR collaboration aims to speed drug discovery

Sanger Institute to share genome-editing expertise with AstraZeneca

The Wellcome Trust Sanger Institute will work collaboratively with AstraZeneca to exploit the full potential of innovative CRISPR-Cas9 technology in the field of drug discovery. CRISPR-Cas9, which allows scientists to make precise changes to genes, will be used in collaborative projects between the pharmaceutical company and the Sanger Institute to identify and validate new drug targets.

American Society of Clinical Oncology highlights Sanger Institute research

American Society of Clinical Oncology highlights Sanger Institute research

Study into the origins of cancer included in prestigious annual report

Research into the origins of cancer led by Wellcome Trust Sanger Institute Director Professor Mike Stratton has been selected for inclusion in the American Society of Clinical Oncology's Annual Report on Progress Against Cancer.

Genetics underpinning antimalarial drug resistance revealed

Genetics underpinning antimalarial drug resistance revealed

Largest genome-wide study of parasite provides clearest picture yet of genetic changes driving artemisinin resistance

The largest genome-wide association study to date of the malaria parasite Plasmodium falciparum unveils a complex genetic architecture that enables the parasite to develop resistance to our most effective antimalarial drug, artemisinin. The results could help to improve early detection of emerging artemisinin resistance.

Novel breast cancer gene found

Novel breast cancer gene found

The BCL11A gene has been identified as being especially active in aggressive subtypes of difficult-to-treat breast cancer.

A new study identifies a gene that is especially active in aggressive subtypes of breast cancer. The research suggests that an overactive BCL11A gene drives triple-negative breast cancer development and progression.

Revamped website unravels mysteries of DNA

Revamped website unravels mysteries of DNA

yourgenome.org relaunch will bring advances in genetics to a wider audience

As genomics transforms healthcare in the UK, a revamped website to inform and inspire the curious about advances in DNA sequencing is set to launch at the Association for Science Education's Annual Conference.

Pages